Bli medlem
Bli medlem

Du är här


PCI Biotech Holding: PCI Biotech signs pre-clinical research collaboration agreement with a top-10 large pharma company

Lysaker 10th September 2015 - PCI Biotech (PCIB) the Norwegian
biopharmaceutical company, reported today that it has signed an agreement
with an undisclosed top-10 large pharma company, with the aim to evaluate
synergistic effects of the PCI technology with their therapeutic nucleic acid
technology. Initially, the purpose of the pre-clinical research program is to
determine whether PCI has the potential to enhance the therapeutic effect of
their nucleic acid technology platform.

The current pre-clinical research agreement covers evaluation of technology
compatibility and synergy based onin vitro
studies. The costs related to the research collaboration will be covered by
the pharma company, which is one of the global leaders in nucleic acid
therapeutics. The companies will evaluate the data generated in this research
collaboration and based on this explore the potential for a further
partnership. The original evaluation period spans over 9 months, but may be
further extended.

"I'm delighted to announce this research agreement with one of the largest
pharma companies in the world. We believe that the PCI technology has the
potential to play a role in the realisation of several new therapeutic
modalities, including cancer immunotherapy and mRNA therapeutics. This
agreement shows that external players share this view
". Per Walday, CEO.

About PCI Biotech
PCI Biotech is a cancer focused biopharmaceutical company headquartered in
Norway and listed on the Oslo Stock Exchange (Axess). The company is
developing therapeutic products based on its proprietary photochemical
internalization (PCI) technology. Originating from world leading research at
the Norwegian Radium Hospital, the PCI technology works by inducing triggered
endosomal release and may be used to unlock the true potential of a wide
array of therapeutic modalities, such as small molecules, vaccines and
nucleic acids.

The company currently has a bile duct cancer program in phase I/II clinical
development. Bile duct cancer is an orphan indication without any approved
medicinal products and a high medical need for better local treatments. It is
an indication well suited for PCI treatment, with easy light access for
intraluminal surface illumination through routine endoscopic methods and an
active generic drug (gemcitabine) significantly enhanced by PCI.

The company is also developing PCI as a CTL (Cytotoxic T Lymphocyte) induction
technology for therapeutic and prophylactic vaccination. It has been
demonstrated bothin vivo
andex vivo
that PCI significantly increases the number of activated antigen-specific CTLs
by enhancing the MHC I antigen presentation of antigen presenting cells. When
applied in the emerging field of cancer immunotherapy, PCI can be used to
enhance the important cytotoxic effect of therapeutic cancer vaccines.

PCI Biotech follows a strategy to create value by improving the effect both of
existing cancer drugs and by realizing the large potential in new
therapeutics, including therapeutic vaccines.

For more information visit:
Contact information:
PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker
Per Walday, CEO,, Mobile: +47 917 93 429

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCI Biotech Holding via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.